SEC 13F Intelligence

Managers / Q3 2024 · view latest →

NVP Associates, LLC

CIK 0001545692 · 1300 EL CAMINO REAL, SUITE 200, MENLO PARK, CA, 94025 · 650-321-8000

Reported Value
$176M
Q3 2024
Positions
8
Filings on Record
14
2019–present window
Filed
Nov 12, 2024
original filing

Summary

Nvp Associates, LLC reported $176M in U.S.-listed holdings across 8 positions for Q3 2024.

The portfolio is heavily concentrated: MBX alone accounts for 31.5% of reported value.

Compared with Q2 2024, the fund opened 2 new positions and exited 0.

Portfolio Metrics

Turnover
+6.0%
vs prior filed quarter
Largest Position
+31.5%
Mbx Biosciences

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $102MQ4 ’22Q1 ’23: $87MQ2 ’23: $115MQ2 ’23Q3 ’23: $112MQ4 ’23: $112MQ4 ’23Q1 ’24: $126MQ2 ’24: $91MQ2 ’24Q3 ’24: $176MQ4 ’24: $187MQ4 ’24Q1 ’25: $112MQ2 ’25: $184MQ2 ’25Q3 ’25: $166MQ4 ’25: $255MQ4 ’25Q1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 100.0%Other: 0.0%
  • Common Stock · 100.0% · $176M
  • Other · 0.0% · $214

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MBXMBX BIOSCIENCES INCNEW+2.14M2.14M+$56M$56M
ZBIOZENAS BIOPHARMA INCNEW+1.84M1.84M+$31M$31M
DAVEDAVE INCHELD+0582.7K+$6M$23M
7WHUDEMY INCHELD+03.11M$4M$23M
TALKTALKSPACE INCHELD+014.70M$3M$31M
GROVGROVE COLLABORATIVE HOLD INCHELD+02.94M$1M$4M
OPENOPENDOOR TECHNOLOGIES INCHELD+04.19M+$670,330$8M
DIGITAL BRANDS GROUP INCHELD+0636$718$214

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

8 positions
#IssuerClass% PortfolioValueShares
1MBXMBX BIOSCIENCES INChistory →COM31.51%$56M2.14M
2ZBIOZENAS BIOPHARMA INChistory →COM17.66%$31M1.84M
3TALKTALKSPACE INChistory →COM17.45%$31M14.70M
4DAVEDAVE INChistory →CLASS A COM NEW13.22%$23M582.7K
57WHUDEMY INChistory →COM13.16%$23M3.11M
6OPENOPENDOOR TECHNOLOGIES INChistory →COM4.76%$8M4.19M
7GROVGROVE COLLABORATIVE HOLD INChistory →COM CL A2.26%$4M2.94M
8DIGITAL BRANDS GROUP INCCOM NEW0.00%$214636

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M5May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$255M6Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$166M5Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$184M7Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$112M6May 12, 202513F-HRchanges · EDGAR ↗
Q4 2024$187M7Feb 10, 202513F-HRchanges · EDGAR ↗
Q3 2024$176M8Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$91M6Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$126M6May 10, 202413F-HRchanges · EDGAR ↗
Q4 2023$112M6Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$112M8Nov 8, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M9Aug 1, 202313F-HRchanges · EDGAR ↗
Q1 2023$87M8May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$102M8Feb 14, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.